HomeRecall LibraryMedication RecallsDue to risk of serious liver injury, FDA restricts use of Ocaliva (obeticholic acid) in primary biliary cholangitis (PBC) patients with advanced cirrhosis
FDA recall notice

Due to risk of serious liver injury, FDA restricts use of Ocaliva (obeticholic acid) in primary biliary cholangitis (PBC) patients with advanced cirrhosis

Due to risk of serious liver injury, FDA restricts use of Ocaliva (obeticholic acid) in primary biliary cholangitis (PBC) patients with advanced cirrhosis

What to do next

Read the issuing agency's notice carefully, compare the product identifiers, and follow the official remedy instructions. RecallDefense helps you keep watch, but the source agency's notice is the authority for action.

View source notice

Source attribution: FDA. Published May 26, 2021.

Continue Exploring Recall Coverage

Keep Watch After Today

Save a product and get notified when a new recall matches it.

Start Monitoring Free